Trial Profile
Randomized Study of Nitazoxanide-Peginterferon, Nitazoxanide-Peginterferon-Ribavirin and Peginterferon-Ribavirin in the Treatment of Chronic Hepatitis C
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 06 Apr 2009
Price :
$35
*
At a glance
- Drugs Nitazoxanide (Primary) ; Peginterferon alfa-2a; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms STEALTHC-1
- Sponsors Romark Laboratories
- 01 Mar 2009 Results published in Gastroenterology.
- 23 Sep 2008 Status changed from active, no longer recruiting to completed.
- 18 Apr 2008 Final results will be presented at EASL 2008.